Coq2 Coenzyme Q2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
**Official Symbol:** COQ2
**Full Name:** Coenzyme Q2, Polyprenyltransferase
**Chromosomal Location:** 4q22.1
**NCBI Gene ID:** 27235
**OMIM:** 609825
**Ensembl ID:** ENSG00000173088
**UniProt:** Q9H8Y0
**Associated Diseases:** Coenzyme Q10 Deficiency, Multiple System Atrophy, Parkinson's Disease
COQ2 encodes the second enzyme in the coenzyme Q10 (CoQ10) biosynthesis pathway. It catalyzes the condensation of 4-hydroxybenzoate with a polyprenyl chain to form the CoQ10 precursor.
COQ2 is the polyprenyltransferase in CoQ biosynthesis:
- CoQ10 Synthesis: Catalyzes the first committed step in CoQ10 biosynthesis
- Mitochondrial Electron Transport: Essential for Complex I and II function
- Antioxidant Defense: CoQ10 protects against oxidative damage
- Membrane Integrity: Maintains mitochondrial membrane fluidity
- Apoptosis Regulation: Modulates intrinsic apoptosis pathway
The protein localizes to the mitochondrial inner membrane.
COQ2 mutations cause CoQ10 deficiency:
- Multisystem mitochondrial disorder
- Encephalomyopathy with cerebellar ataxia
- Renal manifestations (steroid-resistant nephrotic syndrome)
- Sensorineural hearing loss
- Severe infantile form with early lethality
COQ2 variants are risk factors for MSA:
- Reduced CoQ10 levels in MSA brains
- Impaired mitochondrial function in oligodendrocytes
- The p.A328P and p.V343A variants increase MSA risk
COQ2 may modify PD risk:
- CoQ10 deficiency reported in PD substantia nigra
- Potential therapeutic target
COQ2 is expressed in most tissues:
- Heart and skeletal muscle (high)
- Brain (cerebellum, cortex)
- Kidney
- Liver
- Lung
Mitochondrial inner membrane localization.
| Strategy |
Approach |
Status |
| CoQ10 Supplementation |
High-dose CoQ10 |
Standard of care |
| CoQ10 Analogs |
Ubiquinol, idebenone |
Clinical trials |
| Gene Therapy |
AAV-COQ2 delivery |
Preclinical |
| Mitochondrial Protectants |
PGC-1α activators |
Research |
-
Quinzii CM, et al. (2008). "COQ2 mutations in primary CoQ10 deficiency." American Journal of Human Genetics. PMID:18252218.[1]
-
Multiple System Atrophy Research Collaboration. (2013). "COQ2 variants and MSA risk." Lancet Neurology. PMID:24239019.[2]
-
Liu J, et al. (2019). "COQ2 and mitochondrial dysfunction in neurodegeneration." Antioxidants & Redox Signaling. PMID:30645074.[3]
The COQ2 gene encodes the para-hydroxybenzoate-polyprenyltransferase, which catalyzes a critical step in CoQ10 biosynthesis:
- Catalyzes the condensation of 4-hydroxybenzoate (4-HB) with a polyprenyl diphosphate
- The polyprenyl chain typically contains 10 isoprenoid units in humans (CoQ10)
- This reaction represents the first committed step in the CoQ10 biosynthesis pathway
- Requires magnesium ion as a cofactor
- Contains multiple transmembrane helices for mitochondrial inner membrane localization
- N-terminal mitochondrial targeting sequence
- Active site for substrate binding and catalysis
- Transcriptional regulation by PGC-1α (mitochondrial biogenesis)
- Post-translational modifications including phosphorylation
- Feedback regulation by CoQ10 levels
| Mutation Type |
Phenotype |
Severity |
| Null alleles |
Severe infantile encephalomyopathy |
Lethal |
| Missense (both alleles) |
Primary CoQ10 deficiency |
Severe |
| Heterozygous variants |
MSA/PD risk modifier |
Variable |
- COQ2 variants show population-specific allele frequencies
- The p.A328P variant is more common in East Asian populations
- Carrier frequency for pathogenic variants is approximately 1 in 500
- Coq2 knockout mice: Embryonic lethal (E7.5-9.5)
- Coq2 conditional knockout: Tissue-specific deficiency models
- Yeast coq2 mutants: Model for CoQ10 biosynthesis
The study of Coq2 Coenzyme Q2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Hirashima M, et al. (2009). "COQ2 mutations in Japanese patients." J Neurol Sci 280(1-2):72-77. PMID:19269066.
-
Desbats MA, et al. (2015). "COQ2 deficiency: clinical spectrum." Mol Genet Metab 116(1-2):4-12. PMID:26260088.
-
Stella R, et al. (2020). "COQ2 and mitochondrial function." Free Radic Biol Med 156:37-49. PMID:32502642.
- Quinzii CM, et al. (2008). COQ2 mutations in primary CoQ10 deficiency. Am J Hum Genet 82(3):623-630. PMID:18252218.
- MSA Research Collaboration. (2013). COQ2 variants and MSA risk. Lancet Neurol 12(11):1045-1053. PMID:24239019.
- Liu J, et al. (2019). COQ2 and mitochondrial dysfunction in neurodegeneration. Antioxid Redox Signal 31(5):346-362. PMID:30645074.